Truffle Capital vous présente ses dernières actualités – dans cette section vous trouverez  les articles,  les communiqués de presse et les vidéos de Truffle ainsi que des sociétés du portefeuille.

Les dernières lettres de l’innovation de Truffle Capital vous sont également accessibles ci-dessous.

septembre 2010

Truffle Capital


LONDON, UK, September 15, 2010 – Immune Targeting Systems (ITS) Limited (“ITS”), one of the leading developers of synthetic vaccines for mutating viruses, today announced the first patient has been treated in itsPhase-I trial with its synthetic universal influenza vaccine (FP-01). Commencement of trials follows receipt of UK Regulatory Authority (MHRA) approval. Over the same period the company brought in £500,000 new investment from Esperante Ventures (UK). This brings total Series-A funding to £14.5 million from our syndicate of investors HealthCap (Sweden), London Technology Fund (UK), Novartis Venture Fund (US & Basel) and Truffle Capital (France).
Carlton Brown, CEO of ITS, commented: “This represents a major achievement and highlights our delivery of important R&D milestones. In less than three years we have taken a novel vaccine concept to the point of starting clinical testing. Furthermore, en route we have developed extensive validation data for our vaccine platform, meriting imminent expansion of our R&D pipeline”.
The FP-01vaccine holds the promise of being able to target all potential seasonal and pandemic influenza-A strains and protect people from severe influenza disease. Current flu vaccines are known to be less effective in key at-risk market segments such as the elderly, chronically ill and young children – where most of the disease burden occurs. Furthermore, this synthetic and thermostable vaccine could represent a major breakthrough to Governments wishing to create longterm ubiquitous vaccine stockpiles